BA vs MRK: Which Is the Better Buy?
Side-by-side comparison of The Boeing Company and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
The Boeing Company · Industrials
$201.15
+31.7% upside to fair value
Med Conviction
Grade B
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
BA has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BA |
MRK |
| Current Price |
$201.15 |
$147.17 |
| Fair Value Estimate |
$265.00 |
$141.07 |
| Upside to Fair Value |
+31.7%
|
-4.1%
|
| Market Cap |
$159.0B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
28.4x
|
29.6x
|
| Price / Sales |
1.7x
|
5.5x
|
| Price / FCF |
—
|
22.6x
|
| Revenue Growth YoY |
+8.0%
|
+5.1%
|
| Gross Margin |
4.7%
|
75.4%
|
| Operating Margin |
-5.4%
|
16.7%
|
| Return on Equity |
104.8%
|
6.6%
|
| Dividend Yield |
0% |
2.31% |
| FCF Yield |
—
|
4.42%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Boeing is a global aerospace and defense manufacturer spanning commercial airliners, military aircraft, satellites, missile defense, and aftermarket services, with roughly 182,000 employees and a business that remains structurally advantaged by the duopoly economics of large commercial aircraft and the long-cycle, high-switching-cost nature of aerospace platforms. The business quality is currentl…
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
BA |
MRK |
| Zone Low |
$198.75 |
$105.80 |
| Zone High |
$225.25 |
$119.91 |
| In Buy Zone? |
Yes
|
No
|